PUBLICATIONS

Selected publications

• L. Jerby-Arnon and A. Regev
  Mapping multicellular programs from single-cell profiles
  Nature Biotechnology (2022)

• L. Jerby-Arnon, C. Neftel, M. E. Shore, H. R. Weisman, N. D. Mathewson, et al.
  Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
  Nature Medicine, 2021.

• L. Jerby-Arnon, P. Shah, M. S. Cuoco, C. Rodman, M.-J. Su, J. C. Melms, et al.
  A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade
  Cell, 2018.

• L. Jerby-Arnon, N. Pfetzer, Y. Y. Waldman, L. McGarry, D. James, et al.
  Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality
  Cell, 2014.
  Preview: DAISY: Picking Synthetic Lethals from Cancer Genomes

Preprints

• L. Jerby-Arnon, K. Tooley, … , Ana C. Anderson, Aviv Regev
  Pan-cancer mapping of single T cell profiles reveals a TCF1:CXCR6-CXCL16 regulatory axis essential for effective anti-tumor immunity
  bioRxiv, 466532.
  See Preprint Watch, Nature Reviews Immunology

Additional Publications

• O. Ursu, J. T. Neal, E. Shea, P. I. Thakore, L. Jerby-Arnon, et al.
  Massively parallel phenotyping of variant impact in cancer with Perturb-seq reveals a shift in the spectrum of cell states induced by somatic mutations
  Nature Biotechnology, 2022

• R. Kamber, Y. Nishiga, B. Morton, A. Banuelos, A. Barkal, … , L. Jerby-Arnon, I. L. Weissman,
  J. Sage, M. C. Bassik
  Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis
  Nature, 2021.

• C. J. Frangieh, J. C. Melms, P. I. Thakore, K. R. Geiger-Schuller, … , L. Jerby-Arnon, et al.
  Multimodal pooled Perturb-CITE-seq screens in patient models defines mechanisms of cancer immune evasion
  Nature Genetics, 2021.

• G. D. Barnabas, J. S. Lee, T. Shami, M. Harel, L. Beck, M. Selitrennik, L. Jerby-Arnon, et al.
  Serine Biosynthesis Is a Metabolic Vulnerability in IDH2-Driven Breast Cancer Progression
  Cancer Research, 2021.

• N. D. Mathewson, O. Ashenberg, I. Tirosh, S. Gritsch, E. M. Perez, S. Marx, L. Jerby-Arnon, et al.
  Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis
  Cell, 2021.

• B. Izar, I. Tirosh, E. Stover, I. Wakiro, M. Cuoco, …, L. Jerby-Arnon, et al.
  A single-cell landscape of high-grade serous ovarian cancer
  Nature Medicine, 2020.

• A. C. Boroughs, R. C. Larson, N. D. Marjanovic, K. Gosik, A. P. Castano, C. B. M. Porter, S. J. Lorrey, O. Ashenberg, L. Jerby, et al.
  A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling  Domain Revealed by scRNA-Seq
  Molecular Therapy , 2020.

• M. Slyper, C. B. M. Porter, O. Ashenberg, J. Waldman, E. Drokhlyansky, …, L. Jerby-Arnon, et al.
  A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors
  Nature Medicine, 2020.

• D. Liu, B. Schilling, D. Liu, A. Sucker, E. Livingstone, L. Jerby-Arnon, et al.
  Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
  Nature Medicine, 2019.

• A. Li, R. H. Herbst, D. Canner, J. M. Schenkel, O. C. Smith, J. Y. Kim, …, L. Jerby-Arnon, et al.
  IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development
  Cell Reports, 2019.

• A. D. Sahu, J. S Lee, Z. Wang, G. Zhang, R. Iglesias-Bartolome, … , L. Jerby-Arnon, et al.
  Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
  Molecular Systems Biology, 2019.

• J. S. Lee, A. Das, L. Jerby-Arnon, R. Arafeh, N. Auslander, M. Davidson, et al.
  Harnessing synthetic lethality to predict the response to cancer treatment
  Nature Communications, 2018.

• A. Dixit, O. Parnas, B. Li, J. Chen, C. P. Fulco, L. Jerby-Arnon, et al.
  Perturb-Seq: Dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens
  Cell, 2016.

• T. Hyotylainen*, L. Jerby*, E. M. Petaja, I. Mattila, S. Jantti, et al.
  Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease
  Nature Communications, 2016. *Equal contribution.

• L. Zheng, S. Cardaci, L. Jerby, E. D. MacKenzie, M. Sciacovelli, T. I. Johnson, et al.
  Fumarate induces redox-dependent senescence by modifying glutathione metabolism
  Nature Communications, 2015.

• L. Jerby-Arnon and E. Ruppin
  Moving ahead on harnessing synthetic lethality to fight cancer
  Molecular Cell Oncology, 2015.

• L. Jerby, L. Wolf, C. Denkert, G. Y. Stein, M. Hilvo, M. Oresic, T. Geiger, E. Ruppin
  Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer
  Cancer Research, 2012.

• L. Jerby and E. Ruppin
  Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling
  Clinical Cancer Research, 2012.

• O. Folger, L. Jerby, C. Frezza, E. Gottlieb, E. Ruppin, T. Shlomi
  Predicting selective drug targets in cancer through metabolic networks
  Molecular Systems Biology, 2011.

• C. Frezza, L. Zheng, O. Folger, K. N. Rajagopalan, E. D. MacKenzie, L. Jerby, et al.
  Haem oxygenase is synthetically lethal with the tumor suppressor fumarate hydratase
  Nature, 2011.

• L. Jerby, T. Shlomi, E. Ruppin
  Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism
  Molecular Systems Biology, 2010.
  News & Views: Towards whole-body systems physiology

Google scholar | PubMed